{
  "id": "60258ebe1cb411341a0000a8",
  "type": "yesno",
  "question": "Has tocilizumab been assessed against Covid-19?",
  "ideal_answer": "Preliminary clinical results have indicated that tocilizumab, can improve the outcomes of patients with severe or critical COVID-19 while maintaining a good safety profile.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33262810"
  ],
  "snippets": [
    {
      "text": "Preliminary clinical results have indicated that antagonism of the IL-6 receptor (IL-6R), including with the FDA-approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical COVID-19 while maintaining a good safety profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33262810",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}